



→ Jeffrey J. Fessler

Partner
30 Rockefeller Plaza
New York, NY 10112

T: +1.212.634.3067
F: +1.917.438.6133
jfessler@sheppardmullin.com

Jeffrey Fessler is a partner in the Corporate Practice Group in the firm's New York office. Jeffrey is Leader of the firm's Capital Markets and Public Companies Team, as well as the firm's Life Sciences Team.

"Jeffrey Fessler's client service and general level of service is very strong. His professional advice, covering a variety of matters, has been critical to the present and future success of the company."

- Client Testimonial, *Chambers USA 2024*

Areas of Practice

Jeffrey is principally engaged in the practice of corporate and securities law. His practice is focused on the representation of public and private companies, principally in the biotechnology industry. Jeffrey has extensive experience representing investment banks and companies in public offerings and private placements as well as exchange listings and compliance. In addition, Jeffrey has been involved in a wide variety of corporate transactions, including mergers and acquisitions, joint ventures, proxy contests, restructurings and private equity and debt financings, as well as securities disclosure issues and corporate governance. In addition to the biotechnology industry, Jeffrey also represents companies in a variety of industries, including technology, telecommunications, broadcasting and healthcare.

Honors

Leading Life Sciences Lawyer - Corporate, *LMG Life Sciences*, 2022-2025

Recommended Lawyer: Life Sciences, *Legal 500*, 2023-2024

Attorney of the Year, *SmartCEO*, 2014

Experience

Recent Representative Transactions

- Represented Nova Minerals Limited in its IPO and listing on Nasdaq
- Represented Mixed Martial Arts Group Limited in its IPO and listing on NYSE American
- Represented Hepion Pharmaceuticals, Inc. in its \$88.4 million follow-on offering
- Represented Greenwich Life Sciences, Inc. in its \$7.25 million initial public offering, as well as a subsequent \$29.2 million follow-on offering

- Represented Kiromic Biopharma, Inc. in its \$15 million initial public offering
- Represented BioXcel Therapeutics, Inc. in its \$60 million initial public offering
- Represented Aridis Pharmaceuticals, Inc. in its \$26 million initial public offering
- Represented Cardiff Oncology, Inc. in its \$100 million follow-on public offering
- Represented Synergy Pharmaceuticals, Inc. in its \$125 million follow-on public offering
- Represented Synergy Pharmaceuticals, Inc. in its \$200 million Convertible Note Rule 144A offering
- Represented Synergy Pharmaceuticals, Inc. in its \$17.25 million public offering and uplisting to Nasdaq, as well as a subsequent \$51 million public offering
- Represented Northwest Biopharmaceuticals, Inc. in its \$12 million public offering and uplisting to Nasdaq
- Represented Sorrento Therapeutics, Inc. in its \$34.6 million public offering and uplisting to Nasdaq, as well as a subsequent \$28.8 million public offering
- Represented Innovate Biopharmaceuticals, Inc. in its merger with RDD Pharmaceuticals, Ltd.

Articles

- 2025 Top-of-Mind Issues for Life Sciences Companies
01.31.2025
- 2024 Top-of-Mind Issues for Life Sciences Companies
01.25.2024
- 2023 Top-of-Mind Issues for Life Sciences Companies
01.11.2023

Corporate and Securities Law Blog Posts

- "SEC to Expand Confidential Filing Privileges," March 6, 2025
- "SEC Proposes Rules Requiring Climate-Related Disclosures from Registered Public Companies," March 24, 2022
- "SEC Proposes Amendments to Schedule 13 Beneficial Ownership Reporting Requirements," February 24, 2022
- "Delaware Court of Chancery Holds that a Stockholder's Disagreement with a Board's Business Judgment and Intent to Pursue a Proxy Contest is Not a "Proper Purpose" for a Section 220 Demand," November 19, 2019
- "SEC Looks to Modernize Disclosure Approach," September 18, 2019
- "SEC Issues New Guidance on Diversity Disclosure Requirements," February 11, 2019
- "SEC Expands the Definition of 'Smaller Reporting Company'," July 12, 2018
- "New Law Requires SEC to Expand Regulation A+ To Exchange Act Reporting Companies," June 19, 2018
- "SEC Approves New Audit Reporting Standard Requiring Auditors to Disclose More Detailed Information Learned During the Audit," November 2, 2017

FDA Law Blog Posts

- "2025 Top-of-Mind Issues for Life Sciences Companies," January 31, 2025
- "2024 Top-of-Mind Issues for Life Sciences Companies," January 25, 2024

Media Mentions

Aridis Pharmaceuticals' \$26 Million Initial Public Offering
Global Legal Chronicle, 09.25.2018

Sheppard Mullin Adds 4 Corporate Partners In New York
Law360, 10.20.2016

Events

ThinkEquity Conference
The Mandarin Oriental Hotel 80 Columbus Circle (at 60th St) New York, 10023, 10.26.2022

Life Sciences Roundtable: Critical Business Decisions During and After the COVID-19 Pandemic
Webinar, 04.28.2020

Memberships

Certified Public Accountant (New Jersey)

Podcasts & Webinars

Life Sciences Roundtable: Critical Business Decisions During and After the COVID-19
04.28.2020

Practices

Capital Markets

Corporate

Healthcare

Industries

Cannabis

Healthcare

Life Sciences

Space & Satellite

Education

J.D., New York Law School, 1991, *magna cum laude*

B.S., University of Maryland, 1985

Admissions

New York

New Jersey